1196713-64-0

Basic information

• Product Name: C₂₄H₂₇N₃O₄
• Synonyms: C₂₄H₂₇N₃O₄
• CAS NO: 1196713-64-0
• Molecular Weight: 421.496
• Mol File: 1196713-64-0.mol

Chemical Properties

• CAS DataBase Reference: C₂₄H₂₇N₃O₄(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₄H₂₇N₃O₄(1196713-64-0)
• EPA Substance Registry System: C₂₄H₂₇N₃O₄(1196713-64-0)

Safety Data

• Hazardous Substances Data: 1196713-64-0(Hazardous Substances Data)

Upstream product

• 1196713-52-6 C₂₄H₂₇N₃O₆ 
• 5471-82-9 methyl 3-methyl-2-nitrobenzoate 
• 132874-06-7 methyl 3-(bromomethyl)-2-nitrobenzoate 
• 138229-59-1 3-formyl-2-nitrobenzoic acid methyl ester 

Downstream Products

• 1196713-95-7 tert-butyl 6-(7-carbamoyl-2H-indazol-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 

Relevant articles and documents

Indazole formamide compound as well as preparation method and application thereof

The invention belongs to the field of chemical medicines, and particularly relates to an indazole formamide compound as well as a preparation method and application thereof. The invention provides anindazole carboxamide compound or a pharmaceutically acce

Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors

We disclose the development of a novel series of 2-phenyl-2H-indazole-7- carboxamides as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors. This series was optimized to improve enzyme and cellular activity, and the resulting PARP inhibitors display antiproliferation activities against BRCA-1 and BRCA-2 deficient cancer cells, with high selectivity over BRCA proficient cells. Extrahepatic oxidation by CYP450 1A1 and 1A2 was identified as a metabolic concern, and strategies to improve pharmacokinetic properties are reported. These efforts culminated in the identification of 2-{4-[(3S)-piperidin-3-yl] phenyl}-2H-indazole-7-carboxamide 56 (MK-4827), which displays good pharmacokinetic properties and is currently in phase I clinical trials. This compound displays excellent PARP 1 and 2 inhibition with IC50 = 3.8 and 2.1 nM, respectively, and in a whole cell assay, it inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range. Compound 56 was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.